Role of the pharmacist in pre-exposure chemoprophylaxis (PrEP) therapy for HIV prevention.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 4139751)

Published in Pharm Pract (Granada) on March 15, 2009

Authors

Kevin A Clauson1, Hyla H Polen2, Shine A Joseph3, Antonia Zapantis4

Author Affiliations

1: College of Pharmacy - West Palm Beach, Nova Southeastern University . Palm Beach Gardens, FL ( United States ).
2: Integrated Consulting Associates. Jupiter, FL ( United States ).
3: Specialty Resident in Drug Information. College of Pharmacy - West Palm Beach, Nova Southeastern University . Palm Beach Gardens, FL ( United States ).
4: College of Pharmacy, Nova Southeastern University . Fort Lauderdale, FL ( United States ).

Associated clinical trials:

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | NCT00458393

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples (Partners PrEP) | NCT00557245

Bangkok Tenofovir Study | NCT00119106

FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women | NCT00625404

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV | NCT00122486

Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men | NCT00131677

Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia | NCT00078182

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV | NCT00122512

Articles cited by this

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46

Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14

Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep (2005) 5.03

Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials (2007) 4.93

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55

Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep (2003) 4.27

The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? PLoS Med (2005) 3.27

Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr (2006) 2.65

Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials (2007) 2.43

Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep (2005) 2.35

The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One (2008) 2.23

Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA (2006) 1.90

We must not let protestors derail trials of pre-exposure prophylaxis for HIV. PLoS Med (2005) 1.68

Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med (2006) 1.34

A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. AIDS (2003) 0.96